共 85 条
[1]
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin. 71 209-249
[2]
Ferlay J(2018)Current status of diagnosis and treatment of early gastric cancer in China--data from China Gastrointestinal Cancer Surgery Union Zhonghua Wei Chang Wai Ke Za Zhi. 21 168-174
[3]
Siegel RL(2019)Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial Lancet. 393 1948-1957
[4]
Wang Y(2006)Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer N Engl J Med. 355 11-20
[5]
Li Z(2019)Perioperative chemotherapy of oxaliplatin combined with S-1 (SOX) versus postoperative chemotherapy of SOX or oxaliplatin with capecitabine (XELOX) in locally advanced gastric adenocarcinoma with D2 gastrectomy: a randomized phase III trial (RESOLVE trial) Ann Oncol 30 877-542
[6]
Shan F(2020)Prognostic value of lymph node yield after neoadjuvant chemoradiation for gastric cancer Ann Surg Oncol. 27 534-1260
[7]
Al-Batran SE(2016)Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer Eur J Surg Oncol. 42 1253-1356
[8]
Homann N(2017)Lymph node ratio as a prognostic factor in gastric cancer patients following D1 resection. Comparison with the current TNM staging system Eur J Surg Oncol. 43 1350-893
[9]
Pauligk C(2017)The value of N staging with the positive lymph node ratio, and splenectomy, for remnant gastric cancer: a multicenter retrospective study J Surg Oncol. 116 884-62
[10]
Cunningham D(2021)The prognostic value of lymph node ratio after neoadjuvant chemotherapy in patients with locally advanced gastric adenocarcinoma J Gastric Cancer. 21 49-213